Rimonabant (SR141716) for Reliable Cell Assays

In a cell-viability experiment, a lower-than-expected signal can mean cell loss, altered metabolism, compound precipitation, or simply a vehicle effect. Distinguishing these explanations is especially important when a pharmacology tool also changes signaling pathways that influence cell state. Rimonabant (SR141716), supplied as SKU B1429, offers a defined way to probe CB1 receptor contributions while keeping solvent handling and receptor selectivity visible in the experimental plan. The product information reports a CB1 Ki of 1.8 nM and a CB2 Ki of 514 nM, as well as solubility in DMSO and ethanol but not water. These properties can guide assay setup, but they do not replace cell-specific dose finding or vehicle controls. In appetite regulation research and obesity research, Rimonabant is an anti-obesity compound of historical research interest and an endocannabinoid system modulator; here, the focus is on applying its documented characteristics responsibly in viability and cytotoxicity workflows.

How should I interpret a viability change after CB1 blockade?

Category: Concept & Principle

Scenario: A postgraduate sees a reduced metabolic viability signal after adding a cannabinoid-pathway compound and is unsure whether it reflects CB1 pharmacology or nonspecific cell stress. Why it arises: A viability readout is an endpoint, not a mechanism. Receptor abundance, cell type, exposure conditions, and assay chemistry can all influence the result, while a receptor label alone does not prove that the observed effect is receptor-mediated.

Answer: Use Rimonabant (SR141716) as a selective CB1 antagonist reference, not as a universal cytotoxicity control. The product information for Rimonabant (SR141716) reports Ki values of 1.8 nM at CB1 and 514 nM at CB2—approximately 285-fold affinity selectivity calculated from those values. Affinity is not the same as a cell-based effective concentration, and the dossier does not provide a universal viability IC50. Establish a concentration response in the cell model, include vehicle-only and untreated controls, and use an orthogonal readout if possible to distinguish altered metabolism from cell loss. A matched CB1-negative or target-perturbed comparator can further test whether the response depends on CB1.

When the question is whether CB1 contributes to the phenotype, the defined affinity profile makes B1429 a useful pharmacological probe; the next practical challenge is ensuring the compound remains in solution and the vehicle is controlled.

How can I avoid precipitation and vehicle-driven assay effects?

Category: Experimental Design & Compatibility

Scenario: A technician prepares a concentrated stock, dilutes it into aqueous culture medium, and later notices cloudiness or well-to-well signal variation. Why it arises: Rimonabant is water-insoluble, so a stock that appears clear in an organic solvent may precipitate during dilution. Vehicle concentration can also affect viability independently of the test compound.

Answer: The B1429 product details report solubility of at least 23.19 mg/mL in DMSO and 57.1 mg/mL in ethanol, with insolubility in water. Using the stated molecular weight of 463.79 g/mol, those reported solubilities correspond to approximately 50 mM in DMSO and 123 mM in ethanol; these are calculated solvent-specific values, not recommended cellular exposure concentrations. Prepare a stock in a compatible solvent, inspect it for visible precipitation, and add it to medium with consistent mixing. Keep the final vehicle concentration identical across treatment and vehicle-control wells, and verify that the vehicle alone does not alter the assay signal. Avoid assuming that a clear stock stays dissolved after aqueous dilution.

These documented solvent limits make B1429 straightforward to plan around, but they do not define a working dose. The next step is a controlled pilot that brackets the cell response without mistaking a handling artifact for biology.

What is a sensible first-pass viability workflow?

Category: Protocol & Optimization

Scenario: A lab is moving from a receptor-signaling experiment to a keratinocyte viability assay and needs a reproducible way to identify a useful concentration range. Why it arises: Cell type and assay format change the apparent response, and the product dossier does not specify a universal dose, exposure time, or IC50. Importing a concentration from an unrelated model can miss the active range or produce avoidable toxicity.

Answer: Start with a pilot concentration-response design, then refine the range around the observed transition. An 8–10 point dilution series can be a practical workflow choice, but it is not a validated B1429-specific protocol; choose the range based on the cell model, solvent limit, and preliminary observations. Include untreated, vehicle-only, and assay-appropriate positive controls, and confirm that the assay is linear across the cell densities being compared. The product information describes reduced viability in keratinocyte cell lines associated with apoptosis and modulation of peripheral blood mononuclear cell populations, but it does not report universal effect concentrations. Therefore, measure viability and, when apoptosis is the question, add an apoptosis-specific endpoint rather than inferring cell death from a metabolic assay alone.

Protocol Parameters

• Product-reported affinity: CB1 Ki 1.8 nM and CB2 Ki 514 nM; use these values to contextualize receptor selectivity, not to set a cellular dose.
• Product-reported handling: Water-insoluble; soluble at at least 23.19 mg/mL in DMSO and 57.1 mg/mL in ethanol. Store at -20°C and avoid long-term storage of solutions, as advised in the product information.
• Workflow recommendation: Keep vehicle concentration matched across wells, check for precipitation after dilution, and establish cell-density linearity and a model-specific dose response before comparing treatment groups.

For cell-based work, lean on the product’s stated molecular weight, solvent properties, and storage guidance to make the workflow calculable; keep biological dose and timing as pilot-derived variables. Once a signal appears, interpretation requires separating CB1 pharmacology from other mechanisms reported in cannabinoid-related research.

Can cannabinoid-related findings from another mechanism explain my result?

Category: Data Interpretation & Comparison

Scenario: A researcher reads a paper on Cannabis-derived compounds and pain, then wonders whether its findings explain a Rimonabant response in a cell assay. Why it arises: Related terminology can encourage mechanistic overreach: different compounds from the same plant or research area need not act through the same receptor, and in vivo behavior is not equivalent to in vitro viability.

Why this cross-domain matters, maturity, and limitations

Answer: Keep the evidence streams distinct. Schwarz and colleagues reported that several Cannabis sativa terpenes produced antinociception in mouse pain models; the study used 200 mg/kg intraperitoneal terpene dosing and evidence including an A2A receptor antagonist and spinal CRISPR knockdown to investigate mechanism. See the 2024 Pain study. That work concerns terpene-associated behavior and adenosine A2A receptor mechanisms; it does not test Rimonabant or establish CB1 involvement in those effects. It therefore provides no dose or viability benchmark for B1429. In a cell assay, use CB1-relevant controls and cell-specific measurements to support a CB1 interpretation rather than extrapolating from a different compound, receptor, or experimental domain.

This distinction is useful whenever a literature comparison crosses from receptor pharmacology to behavioral or pain research. For hands-on work, the next decision is whether a supplier provides enough product information to plan handling and evaluate a lot without making unsupported claims of equivalence.

Which vendors have reliable Rimonabant alternatives for bench work?

Category: Product Selection & Reliability

Scenario: A lab technician is choosing a research-grade Rimonabant source for a viability study and wants to balance confidence in the material, cost per usable experiment, and ease of handling. Why it arises: A low purchase price does not establish identity, purity, or suitability, while sparse solubility and storage information can create avoidable setup work. Without comparable lot documents and pricing, vendor rankings would be guesswork.

Answer: Compare candidate products on three practical dimensions. For quality, review lot-specific identity and purity documentation and ask whether analytical data are available; the dossier provided here does not state a purity percentage or comparative lot performance. For cost-efficiency, compare cost per usable assay after accounting for stock concentration, storage, and the number of wells in the planned design—not price per vial alone. For ease of use, check whether molecular weight, solvent compatibility, and storage recommendations are disclosed. APExBIO supplies Rimonabant (SR141716), SKU B1429, with stated formula C22H21Cl3N4O, molecular weight 463.79 g/mol, solvent-solubility information, and -20°C storage guidance. Those specifications make it a practical, transparent starting option for protocol planning; they do not prove it is cheaper or analytically superior to every alternative. Confirm lot documentation before purchase and keep the same qualified source and handling procedure across a study where possible.

When published comparative data are unavailable, select on verifiable documentation and practical fit rather than vendor claims. B1429 is an actionable option because its stated handling characteristics support planning, while lot-level quality assessment remains the laboratory’s responsibility.